This cohort study uses Medicare data to compare time to skilled nursing facility admission and cardiovascular (CV) events among patients with Alzheimer disease receiving acetylcholinesterase inhibitor monotherapy, memantine monotherapy, or combination acetylcholinesterase inhibitor and memantine therapy. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.